What is NxStage Medical's stock symbol?
NxStage Medical trades on the NASDAQ under the ticker symbol "NXTM."
Where is NxStage Medical's stock going? Where will NxStage Medical's stock price be in 2017?
6 analysts have issued 1 year target prices for NxStage Medical's stock. Their forecasts range from $21.00 to $38.00. On average, they anticipate NxStage Medical's stock price to reach $30.80 in the next year.
When will NxStage Medical announce their earnings?
NxStage Medical is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
What are analysts saying about NxStage Medical stock?
Here are some recent quotes from research analysts about NxStage Medical stock:
- Jefferies Group LLC analysts commented, "Home hemodialysis (HHD) in skilled nursing facilities (SNF) is a significant opportunity for NXTM. HHD penetration is already approaching 6% in the most developed states v. less than 2% for the market as a whole; a disparity explained to a large degree by SNF adoption. The regulatory underpinnings can be debated, but even modest assumptions for continued adoption in SNFs supports 20%+ revenue growth at NXTM. We raise our PT to $38, 5x 2018 sales." (2/6/2017)
According to Zacks Investment Research, "NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. " (1/5/2017)
Who owns NxStage Medical stock?
NxStage Medical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (11.34%), Deerfield Management Co. (6.58%), Perceptive Advisors LLC (2.98%), Cortina Asset Management LLC (2.11%), State Street Corp (1.87%) and Arrowstreet Capital Limited Partnership (0.95%). Company insiders that own NxStage Medical stock include Barry M Straube, Craig W Moore, Daniel A Giannini, Earl R Lewis, Jeffrey H Burbank, Joseph E Turk Jr, Joseph E Turk, Jr, Matthew W Towse, Robert S Brown and Winifred L Swan.
Who sold NxStage Medical stock? Who is selling NxStage Medical stock?
NxStage Medical's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Cortina Asset Management LLC, Employees Retirement System of Texas, Two Sigma Investments LP, Nicholas Investment Partners LP, Continental Advisors LLC and William Blair Investment Management LLC. Company insiders that have sold NxStage Medical stock in the last year include Craig W Moore, Daniel A Giannini, Jeffrey H Burbank, Joseph E Turk Jr, Matthew W Towse, Robert S Brown and Winifred L Swan.
Who bought NxStage Medical stock? Who is buying NxStage Medical stock?
NxStage Medical's stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Marshall Wace LLP, Arrowstreet Capital Limited Partnership, Deerfield Management Co., Loomis Sayles & Co. L P, Advisory Research Inc., Elkfork Partners LLC and A.R.T. Advisors LLC. Company insiders that have bought NxStage Medical stock in the last two years include Barry M Straube and Earl R Lewis.
How do I buy NxStage Medical stock?
Shares of NxStage Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of NxStage Medical stock cost?
One share of NxStage Medical stock can currently be purchased for approximately $29.16.